Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Atrial fibrillation remains a common and challenging cardiac arrhythmia, particularly in hypertensive patients, who face a ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

Three risk factors—high blood pressure, atrial fibrillation, and smoking—are more likely to cause severe strokes, meaning ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of ...